Does rifaximin improve driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy?
Patients with MHE significantly improve driving simulator performance after treatment with rifaximin, compared with placebo.
The Akt-Caspase 3 signal pathway may be involved in these processes.